These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings - Elevance Health (NYSE:EL

CMS said Medicare Advantage payments to private insurers will rise 2.48% next year, implying about $13 billion in additional payments, and 4.98% after risk-score trends. UNH, HUM, CNC and ELV shares rose 5% to 11% in extended trading. CVS and MOH also gained, after a January proposal for a near-flat increase.

Elevance Health filed a complaint on July 27, 2026, in the US District Court for the Southern District of New York against managed care organization Hamaspik, Inc. and four of its own former employees. According to the filing, Hamaspik has run a "coordinated scheme" since December 2025 to hire the people who run Elevance's New York Managed Long-Term Care (MLTC) and Fully Integrated Dual Eligible Special Needs (FIDE) plans, which combine Medicare and Medicaid coverage in a single product.

Simply Wall St reports Elevance Health (ELV) paired Q2 results with higher full-year 2026 diluted EPS guidance of at least $20.10, despite lower quarterly net income. It cites ELV’s 90-day return of 12.36% and 1-year total shareholder return of 33.94%. A valuation narrative pegs fair value at $436.52 versus $389.09 prior close, implying undervaluation, contingent on Medicaid margins and medical cost trends.

Elevance Health (ELV) reported adjusted EPS of $7.45 versus $6.27 consensus and raised 2026 adjusted diluted EPS guidance to at least $27, with Medicare Advantage targeting at least a 2% operating margin. Shares fell 8.5% as Medicaid operating margin guidance stayed at -1.75%. Elevance said it will exit D.C. Medicaid and expects further Medicaid market exits in 12-18 months.

Elevance Health (NYSE:ELV) management said 2026 is expected to be the trough year for Medicaid margins, with improvement later supported by better rate alignment and care management actions. The company expects to exit additional low-sustainable Medicaid markets over 12 to 18 months. It reported Q2 operating cash flow of $1.9B and raised full-year outlook to at least $6B.

Elevance Health (ELV) shares fell in premarket after its Q2 results showed margin pressure in the Health Benefits segment. Adjusted operating margin fell to 3.6% from 5.0% a year earlier. Despite revenue of $50.47B and adjusted EPS of $7.45, investors cited weaker underlying profitability. Peers including UNH, MOH, HUM, CNC and CVS also dropped ahead of UNH earnings.